Abstract
Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells(Teffs) on the β cell. Recent literature now suggests that a failure of a second T cell subtype, known as regulatory T cells (Tregs), plays a critical role in the development of T1DM. During immune homeostasis, Tregs counterbalance the actions of autoreactive Teff cells, thereby participating in peripheral tolerance. An imbalance in the activity between Teff and Tregs may be crucial in the breakdown of peripheral tolerance, leading to the development of T1DM. In this review, we summarize our current understanding of Treg function in health and in T1DM, and examine the effect of experimental therapies for T1DM on Treg cell number and function in both mice and humans.
Keywords: Autoimmunity, effector T cells, regulatory T cells, Teffs, Tregs, Type 1 diabetes mellitus, autoimmune disease, hyperglycemic, phenotype, antigens, autoantigens, viral infection, cytokines, insulitis, chemokines
Current Molecular Medicine
Title:Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Volume: 12 Issue: 10
Author(s): S.M. Cabrera, M.R. Rigby and R.G. Mirmira
Affiliation:
Keywords: Autoimmunity, effector T cells, regulatory T cells, Teffs, Tregs, Type 1 diabetes mellitus, autoimmune disease, hyperglycemic, phenotype, antigens, autoantigens, viral infection, cytokines, insulitis, chemokines
Abstract: Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells(Teffs) on the β cell. Recent literature now suggests that a failure of a second T cell subtype, known as regulatory T cells (Tregs), plays a critical role in the development of T1DM. During immune homeostasis, Tregs counterbalance the actions of autoreactive Teff cells, thereby participating in peripheral tolerance. An imbalance in the activity between Teff and Tregs may be crucial in the breakdown of peripheral tolerance, leading to the development of T1DM. In this review, we summarize our current understanding of Treg function in health and in T1DM, and examine the effect of experimental therapies for T1DM on Treg cell number and function in both mice and humans.
Export Options
About this article
Cite this article as:
Cabrera S.M., Rigby M.R. and Mirmira R.G., Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus, Current Molecular Medicine 2012; 12 (10) . https://dx.doi.org/10.2174/156652412803833634
DOI https://dx.doi.org/10.2174/156652412803833634 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploring N<sup>1</sup>-p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment
CNS & Neurological Disorders - Drug Targets GLP-1, Incretin Mimetics and DPP 4 Inhibitors: New Ways in the Treatment of Type 2 Diabetes
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Probing Gallic Acid for Its Broad Spectrum Applications
Mini-Reviews in Medicinal Chemistry ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Identifying Knowledge Deficits of Food Insecure Patients with Diabetes
Current Diabetes Reviews Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Energy Metabolism in the Normal and in the Diabetic Heart
Current Pharmaceutical Design Effects of Mulberry on The Central Nervous System: A Literature Review
Current Neuropharmacology Age and High-Fat Diet Effects on Glutamine Synthetase Immunoreactivity in Liver and Hippocampus and Recognition Memory in Mice
Current Aging Science Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Preeclampsia and the Future Development of Cardiovascular Disease: A Review
Current Women`s Health Reviews Cholesterol Oxidation Products and Disease: An Emerging Topic of Interest in Medicinal Chemistry
Current Medicinal Chemistry Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial
Current Rheumatology Reviews Plasmid DNA-based Gene Transfer with Ultrasound and Microbubbles
Current Gene Therapy Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Diabetic Nephropathy: Causes and Managements
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets